TALPHERA, INC. quarterly report, Q2 FY2012

Business context and reporting period

AcelRx Pharmaceuticals, Inc. (the registrant named in this filing; metadata identifies Talphera, Inc.) filed this unaudited Form 10-Q for the quarter ended June 30, 2012. It was a development-stage specialty pharmaceutical company developing treatments for acute and breakthrough pain, with no commercial product revenue.

Financial results and liquidity

Amounts are in millions of dollars except per-share data. Quarterly and year-to-date comparisons are to the corresponding 2011 periods.

At June 30, cash and cash equivalents were $7.542 million and short-term investments were $24.391 million, totaling $31.933 million. Current assets were $33.690 million and current liabilities $10.693 million, implying working capital of approximately $23.0 million. Total assets were $36.644 million; total liabilities were $29.016 million.

Debt carrying value was approximately $19.3 million, net of discounts ($7.013 million current and $12.322 million long-term). The Hercules loan bears 8.5% interest. Principal-and-interest installments began July 1, 2012; the filing describes monthly payments of approximately $742,000. Operating cash burn increased as clinical development advanced. The filing does not provide meaningful commercial margins, as the company had no product sales.

Material changes versus the prior comparable period

• First-half R&D expense more than doubled, increasing 104% to $10.165 million, primarily from ARX-01 Phase 3 trial costs. Q2 R&D rose 78% year over year.
• First-half net loss increased to $14.259 million from $7.967 million; first-half operating cash use rose to $12.100 million from $5.026 million.
• Cash, cash equivalents and investments declined to $31.933 million from $35.785 million at year-end 2011, despite $9.1 million of net proceeds from the June private placement.
• In the private placement, the company issued 2.922 million shares and warrants for up to 2.630 million shares, raising $10.0 million gross. The warrants were recorded as a $5.478 million liability at quarter-end, making reported earnings sensitive to fair-value changes.
• Shares outstanding increased to 22.625 million from 19.568 million at December 31, 2011.

Outlook, commentary and key risks

• Management estimated existing cash, cash equivalents, investments and grant funding would support planned operations into the second quarter of 2013. It also said additional capital or collaborations would be needed for future operations; funding availability and terms were uncertain.
• Two ARX-01 Phase 3 trials had begun. The third was planned for Q3 2012. Top-line results were expected in Q4 2012 for the first two trials and Q1 2013 for the third. These were forward-looking expectations, not guarantees.
• The $5.6 million USAMRMC grant for ARX-04 received a no-cost extension through May 31, 2013; Phase 2 initiation remained contingent on government review and approval of the proposed protocol. Development of ARX-02 and ARX-03 depended on additional funding or partnerships.
• Principal risks include clinical-trial outcomes or delays, FDA review of a drug-device combination and opioid-related restrictions, reliance on third-party manufacturing and CROs, controlled-substance supply and DEA quotas, and the need to raise further capital while servicing secured debt.
• The filing reported no material pending litigation, no off-balance-sheet arrangements, and effective disclosure controls. Management reported no significant change in internal control over financial reporting during the quarter.
• The $350,000 decrease in the private-placement warrant fair value benefited Q2 and first-half other income; first-half 2011 other income included prior-period warrant and convertible-note option items. These non-operating valuation and transaction items affect period comparisons.

Important facts for investors to verify

• Whether ARX-01 trials met enrollment, safety and efficacy objectives, and whether results and regulatory-submission timing matched the stated expectations.
• Actual cash burn and remaining runway against management’s Q2 2013 estimate, including the effect of scheduled Hercules payments.
• Availability, cost and dilution or restrictive terms of additional financing or partnership arrangements.
• USAMRMC approval and funding status for ARX-04, and the timing and scope of the grant-supported work.
• Potential changes in the warrant liability and related reported income or expense, as well as the dilution potential of outstanding warrants and equity awards.